Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
Pharmacoeconomics - Open|June 27, 2018
Influence of Idiopathic Pulmonary Fibrosis Progression on Healthcare Resource UseAlex Diamantopoulos, Toby M Maher, Nils Schoof, et al.Expert Review of Pharmacoeconomics & Outcomes Research|October 1, 2011
Cost-effectiveness of rivaroxaban versus heparins for prevention of venous thromboembolism after total hip or knee surgery in SwedenLars Ryttberg, Alex Diamantopoulos, Fiona Forster, et al.Comprehensive Psychiatry|January 25, 2020
Vagus nerve stimulation (VNS) therapy in patients with treatment resistant depression: A systematic review and meta-analysisJuliana M Bottomley, Corinne LeReun, Alex Diamantopoulos, et al.Journal of Medical Economics|March 10, 2011
An indirect comparison, via enoxaparin, of rivaroxaban with dabigatran in the prevention of venous thromboembolism after hip or knee replacementCorinne Lereun, Phillip Wells, Alex Diamantopoulos, et al.BMJ Open Gastroenterology|August 16, 2019
Tofacitinib for the treatment of moderately to severely active ulcerative colitis: a systematic review, network meta-analysis and economic evaluationChristoph Lohan, Alex Diamantopoulos, Corinne LeReun, et al.Pharmacoeconomics|March 2, 2018
The Burden of Illness of Idiopathic Pulmonary Fibrosis: A Comprehensive Evidence ReviewAlex Diamantopoulos, Emily Wright, Katerina Vlahopoulou, et al.Advances in Therapy|December 27, 2021
Using Data on Survival with Idiopathic Pulmonary Fibrosis to Estimate Survival with Other Types of Progressive Fibrosis Interstitial Lung Disease: A Bayesian FrameworkBryony Langford, Alex Diamantopoulos, Toby M Maher, et al.Journal of Medical Economics|April 13, 2012
Cost-effectiveness of rivaroxaban in the prevention of venous thromboembolism: A Canadian analysis using the Ontario Ministry of Health PerspectiveHeather McDonald, Alex Diamantopoulos, Philip Wells, et al.Pharmacoeconomics|May 24, 2014
Tocilizumab in the treatment of rheumatoid arthritis: a cost-effectiveness analysis in the UKAlex Diamantopoulos, A Finckh, T Huizinga, et al.Pharmacoeconomics|September 4, 2021
The Challenges of Outcomes-Based Contract Implementation for Medicines in EuropeNatalie Bohm, Sarah Bermingham, Frank Grimsey Jones, et al.Pageof 2